Alkermes plc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 99.90% for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2015-02-24
- Alkermes plc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2014 was 99.90%.
- Alkermes plc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2013 was -20.50%.
- Alkermes plc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2012 was -8.40%, a 700.00% decline from fiscal 2011.
- Alkermes plc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2011 was 1.40%, a 75.00% increase from fiscal 2010.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|---|
| 2014-12-31 | 99.90% 10-K · filed 2015-02-24 | |
| 2013-12-31 | -29.60% 10-K · filed 2015-02-24 | |
| 2013-03-31 | -20.50% 10-K · filed 2015-02-24 | |
| 2012-03-31 | -8.40% 10-KT · filed 2014-02-27 | |
| 2011-03-31 | 1.40% 10-K · filed 2013-05-23 | |
| 2010-03-31 | 0.80% 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |